Picture Of Wellness Acupuncture & Chinese Medicine

Fisher Wallace Device

More than 20 published studies prove the safety and effectiveness of the Fisher Wallace Stimulator®. The patented device has been cleared by the FDA to treat depression, anxiety, chronic pain and insomnia by gently stimulating the brain to produce serotonin, endorphins and other neurochemicals. It is safe to use in conjunction with any medication for 20 minutes once or twice a day. This therapy can be added to any Acupuncture, or Acupressure session at NO additional charge. Devices can also be purchased through my office.

For more information please visit:
http://www.fisherwallace.com/pages/published-research

"Columbia University Associate Clinical Professor of Psychiatry Richard P. Brown says he has used the device with 400 severely depressed patients and that more than 70% find relief -- about twice the rate of anti-depressants.– The Wall Street Journal

"I have had great success using the device to treat severe, chronic insomnia in patients who are resistant to pharmacotherapy. Also, patients who seek a drug-free alternative to treat insomnia have used the Fisher Wallace Stimulator to reduce or eliminate their dependence on drugs."– Andres San Martin, M.D.
Assistant Clinical Professor of Psychiatry, Columbia University

"But since I couldn't stop talking about my good mood and hypercharged focus, my friends stopped laughing and started asking if they could borrow it. I'm reluctant to let go of my stimulator, however."- ELLE Magazine

"One of four technologies innovating mental health."– Forbes

 

FISHER WALLACE DEVICE TREATMENT $35/25 minutes Relieves mild to moderate anxiety and depression.
Patent-pending neuromodulation technology delivers low-dose, pulsed, alternating current stimulation (tACS) which, as a type of non-invasive brain stimulation, has been shown to induce neural plasticity and entrain neural oscillations. Multiple clinical trials, including a bipolar II depression study at Mount Sinai Beth Israel Hospital, a Parkinson's study at the University of Maryland, three pilot studies during the height of the pandemic, a pivotal depression trial in 2022 that will be used to obtain a CE Mark in Europe for the acute treatment of depression in women, and a real world evidence anxiety study with the Seattle Police Department.